IL259998A - Polymorphic crystalline forms of obeticholic acid - Google Patents

Polymorphic crystalline forms of obeticholic acid

Info

Publication number
IL259998A
IL259998A IL259998A IL25999818A IL259998A IL 259998 A IL259998 A IL 259998A IL 259998 A IL259998 A IL 259998A IL 25999818 A IL25999818 A IL 25999818A IL 259998 A IL259998 A IL 259998A
Authority
IL
Israel
Prior art keywords
crystalline forms
obeticholic acid
polymorphic crystalline
polymorphic
obeticholic
Prior art date
Application number
IL259998A
Other languages
English (en)
Hebrew (he)
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55650649&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL259998(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US14/979,005 external-priority patent/US9982008B2/en
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of IL259998A publication Critical patent/IL259998A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL259998A 2015-12-22 2018-06-13 Polymorphic crystalline forms of obeticholic acid IL259998A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/979,005 US9982008B2 (en) 2012-06-19 2015-12-22 Preparation and uses of obeticholic acid
PCT/US2016/012651 WO2017111979A1 (en) 2015-12-22 2016-01-08 Polymorphic crystalline forms of obeticholic acid

Publications (1)

Publication Number Publication Date
IL259998A true IL259998A (en) 2018-07-31

Family

ID=55650649

Family Applications (1)

Application Number Title Priority Date Filing Date
IL259998A IL259998A (en) 2015-12-22 2018-06-13 Polymorphic crystalline forms of obeticholic acid

Country Status (15)

Country Link
EP (1) EP3394081A1 (zh)
JP (1) JP2018538331A (zh)
KR (1) KR20180095070A (zh)
CN (1) CN108495858A (zh)
AU (1) AU2016375566A1 (zh)
BR (1) BR112018012590A2 (zh)
CA (1) CA3009149A1 (zh)
CL (1) CL2018001720A1 (zh)
CO (1) CO2018006701A2 (zh)
EA (1) EA201891491A1 (zh)
IL (1) IL259998A (zh)
MX (1) MX2018007776A (zh)
PH (1) PH12018501318A1 (zh)
SG (1) SG11201805235XA (zh)
WO (1) WO2017111979A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105801653B (zh) * 2014-12-30 2018-04-17 苏州晶云药物科技有限公司 奥贝胆酸的晶型a及其制备方法
WO2018211413A1 (en) * 2017-05-15 2018-11-22 Dr. Reddy’S Laboratories Limited Solid forms of obeticholic acid and process for preparation
CN109280071A (zh) * 2017-07-19 2019-01-29 东莞东阳光药物研发有限公司 奥贝胆酸的晶型及其制备方法
CN107383139A (zh) * 2017-08-09 2017-11-24 杭州和泽医药科技有限公司 一种3α‑羟基‑7‑氧代‑5β‑胆烷酸新衍生物制备奥贝胆酸的方法
CZ31099U1 (cs) * 2017-09-05 2017-10-17 Zentiva, K.S. Krystalické formy (3a,5B,6a,7a)-6-ethyl-3,7- dihydroxycholan-24-ové kyseliny
CN109485687A (zh) * 2017-09-12 2019-03-19 成都弘达药业有限公司 奥贝胆酸的晶型j及其制备方法
WO2019106043A1 (en) 2017-11-29 2019-06-06 Hexal Ag Pharmaceutical composition comprising obeticholic acid
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
CN113264972B (zh) * 2020-02-14 2024-07-12 四川科伦药物研究院有限公司 一种制备奥贝胆酸的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20050912A1 (it) * 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
JP2015521621A (ja) * 2012-06-19 2015-07-30 インターセプト ファーマシューティカルズ， インコーポレイテッド オベチコール酸の調製、使用および固体形態
CN106459136B (zh) * 2014-09-28 2018-06-26 江苏盛迪医药有限公司 一种奥贝胆酸的制备方法
MX2017006563A (es) * 2014-11-19 2018-01-26 Nzp Uk Ltd Esteroides de 6-alquil-7-hidroxi-4-en-3-ona como intermedios para la produccion de moduladores esteroides del receptor x farnesoide (fxr).
WO2016079519A1 (en) * 2014-11-19 2016-05-26 Dextra Laboratories Limited 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal fxr modulators
WO2016079520A1 (en) * 2014-11-19 2016-05-26 Dextra Laboratories Limited 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators
WO2016079518A1 (en) * 2014-11-19 2016-05-26 Dextra Laboratories Limited 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators

Also Published As

Publication number Publication date
AU2016375566A1 (en) 2018-07-05
CN108495858A (zh) 2018-09-04
CA3009149A1 (en) 2017-06-29
EA201891491A1 (ru) 2018-11-30
MX2018007776A (es) 2018-08-09
CL2018001720A1 (es) 2018-08-10
JP2018538331A (ja) 2018-12-27
WO2017111979A1 (en) 2017-06-29
KR20180095070A (ko) 2018-08-24
PH12018501318A1 (en) 2019-02-18
CO2018006701A2 (es) 2018-07-10
EP3394081A1 (en) 2018-10-31
SG11201805235XA (en) 2018-07-30
BR112018012590A2 (pt) 2018-12-04

Similar Documents

Publication Publication Date Title
IL263429A (en) Crystalline forms of a triazolopyrimidine compound
IL259998A (en) Polymorphic crystalline forms of obeticholic acid
HK1252845A1 (zh) 勞拉替尼游離碱的結晶形式
SI3380554T1 (sl) Kristalne oblike per-kloro-gama-ciklodekstrinov
HK1244274A1 (zh) C21h22ci2n4o2的晶型
HK1247125A1 (zh) 結晶化合物
PL3113773T3 (pl) Krystaliczne postaci grapiprantu
PL3529236T3 (pl) Krystaliczne formy erawacykliny
PL3532457T3 (pl) Postacie krystaliczne hydroksynorketaminy
IL253479A0 (en) Crystalline forms of efinconazole
IL269073A (en) Crystalline forms of obeticholic acid
IL269792B (en) Crystalline forms of (s)–apoxolner
HK1252842A1 (zh) 噻吩並嘧啶化合物的結晶形式
EP3207034A4 (en) Anhydrous crystalline form of s-equol
HK1255148A1 (zh) 結晶形式
GB201518589D0 (en) Crystalline form of tetraacetylethylenediamine
IL270937A (en) Crystalline forms of saltalicib
PT3191444T (pt) Recristalização da ubidecarenona para biodisponilibilidade melhorada